These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 18263768)
1. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Bunn PA; Thatcher N Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768 [TBL] [Abstract][Full Text] [Related]
2. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Bunn PA; Thatcher N Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773 [TBL] [Abstract][Full Text] [Related]
3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
4. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T; Liu G; Tsao MS Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292 [TBL] [Abstract][Full Text] [Related]
6. [Second-line treatment and targeted therapy of advanced lung cancer]. Nakamura Y; Yamamoto N Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168 [TBL] [Abstract][Full Text] [Related]
7. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. Crawford J J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580 [TBL] [Abstract][Full Text] [Related]
8. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future]. Bergot E; Levallet G; Zalcman G Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836 [TBL] [Abstract][Full Text] [Related]
9. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Ray M; Salgia R; Vokes EE Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771 [TBL] [Abstract][Full Text] [Related]
13. Use of novel second-line targeted therapies in non-small cell lung cancer. Massarelli E; Herbst RS Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825 [TBL] [Abstract][Full Text] [Related]
15. New antiangiogenetic agents and non-small cell lung cancer. Gridelli C; Rossi A; Maione P Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002 [TBL] [Abstract][Full Text] [Related]
16. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959 [TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Pennell NA; Lynch TJ Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226 [TBL] [Abstract][Full Text] [Related]
18. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Batus M; Fidler MJ; Bonomi PD Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630 [TBL] [Abstract][Full Text] [Related]
19. Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? Passaro A; Cortesi E; de Marinis F Expert Rev Anticancer Ther; 2011 Oct; 11(10):1587-97. PubMed ID: 21999132 [TBL] [Abstract][Full Text] [Related]
20. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Hirsch FR Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]